Lupin has entered into a strategic collaboration with Laboratorios ERN S.A. (ERN), a well-established Spanish pharmaceutical company, for the launch of Luforbec (beclometasone/formoterol) 100/6, a fixed dose combination in a pressurized metered dose inhaler, for the treatment of adult asthma and chronic obstructive pulmonary disease, in Spain.
This collaboration combines the company’s global respiratory expertise and proven pMDI manufacturing excellence and ERN’s robust national reach and deep customer relationships, marking an exciting milestone in expanding high-quality respiratory care to patients across Spain.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1800.00 |
| Dr. Reddys Lab | 1276.70 |
| Cipla | 1385.80 |
| Zydus Lifesciences | 1104.00 |
| Lupin | 2280.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: